This lecture identifies targetable pathways that drive specific RCC histologies and distinguish which renal cell carcinoma histologies can respond to tyrosine kinase inhibitors, immune checkpoint blockade, or cytotoxic chemotherapy.
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.